Website profile

Biopharma Apac

Stay informed on the latest biopharmaceutical news, trends, and developments in Asia Pacific with BioPharma APAC. BioPharma Asia ( APAC ) provides in-depth analysis, insights, and expert commentary on drug development, regulatory updates, and industry partnerships in the region.

  • 58articles · 30d
  • 2+ day agolatest article
  • Aug 15, 2026earliest in window
  • 97%with images
  • 216avg words
articles per day
Categories
  • Medical 43
  • Health & Wellness 35
  • Economy, Business & Finance 22
  • Health 20
  • Business & Industrial 18
  • Science & Technology 16
  • Science & Nature 7
  • Finance & Business 6

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

BioPharma APAC
biopharmaapac.com > news > 51 > 8421 > bgi-genomics-unveils-digital-life-twin-framework-for-predictive-health-management.html

BGI Genomics Unveils Digital Life Twin Framework for Predictive Health Management

2+ day, 20+ hour ago   (75+ words) 11 September 2026 | Friday | News Anchored by the Life Index system and built on precise risk stratification and systematic health assessments, this model connects upstream to BGI Genomics' full portfolio of multi-omics tests and interventions while empowering downstream healthcare providers and health…...

BioPharma APAC
biopharmaapac.com > news > 43 > 8380 > convergen-raises-15m-seed-to-accelerate-targeted-protein-degradation-therapies.html

Convergen Raises $15M Seed+ to Accelerate Targeted Protein Degradation Therapies

1+ week, 4+ day ago   (60+ words) 02 September 2026 | Wednesday | News The proceeds will be used to further advance Convergen's proprietary degrader platform and accelerate its pipeline for neurodegenerative disorders and other protein aggregation diseases. Two Chairs, 11,000 Kilometres Apart: The Human Cost of Asia’s Plasma Dependence China Plus…...

BioPharma APAC
biopharmaapac.com > news > 123 > 8375 > data4life-monash-health-partner-to-accelerate-clinical-trials-and-real-world-evidence-generation.html

Data4Life, Monash Health Partner to Accelerate Clinical Trials and Real-World Evidence Generation

1+ week, 5+ day ago   (180+ words) 01 September 2026 | Tuesday | News Data4Life and Monash Health have partnered to optimize clinical trial design and execution, complemented by educational workshops and professional training programs, with a shared commitment to improving patient outcomes. The Global Relations Office is a new site launched…...

Google News
biopharmaapac.com > news > 92 > 8378 > thermo-fisher-strengthens-china-focus-as-biopharma-innovation-gains-global-momentum.html

Thermo Fisher Strengthens China Focus as Biopharma Innovation Gains Global Momentum

1+ week, 5+ day ago   (344+ words) 01 September 2026 | Tuesday | News Thermo Fisher Scientific is reinforcing its commitment to China as the country emerges as an increasingly important source of global biopharmaceutical innovation, with Chairman and CEO Marc Casper highlighting opportunities to support Chinese drug developers across discovery,…...

BioPharma APAC
biopharmaapac.com > news > 18 > 8370 > dualitybio-genentech-ink-1b-plus-deal-to-develop-next-generation-adcs-against-drug-resistant-tumours.html

DualityBio, Genentech Ink $1B-Plus Deal to Develop Next-Generation ADCs Against Drug-Resistant Tumours

1+ week, 6+ day ago   (234+ words) 31 August 2026 | Monday | News DUALITYBIO Inc. announced that it has entered into a collaboration and license agreement with Genentech, a member of the Roche Group, to develop next-generation antibody-drug conjugates ("ADCs") built on the Company's proprietary DualityBio Unique Payload Antibody Conjugate…...

BioPharma APAC
biopharmaapac.com > news > 34 > 8368 > formosa-pharmaceuticals-files-european-cta-for-tsy-110-potential-first-kadcyla-biosimilar-in-regulated-markets.html

Formosa Pharmaceuticals Files European CTA for TSY-110, Potential First Kadcyla Biosimilar in Regulated Markets

1+ week, 6+ day ago   (86+ words) 31 August 2026 | Monday | News Designed following regulatory guidance from both US and EU authorities, the upcoming trial will evaluate the safety, tolerability, pharmacokinetics, and immunogenicity profile of TSY-110 compared with the reference product. This milestone advances Formosa Pharmaceuticals' and EirGenix's shared…...

BioPharma APAC
biopharmaapac.com > news > 75 > 8353 > astri-saint-francis-university-partner-to-advance-ai-enabled-biomaterials-and-digital-health.html

ASTRI, Saint Francis University Partner to Advance AI-Enabled Biomaterials and Digital Health

2+ week, 4+ day ago   (215+ words) 26 August 2026 | Wednesday | News Ir Dr Ted Suen, Chief Executive Officer of ASTRI (left) and Professor Stephen Cheung Yan-leung, President of Saint Francis University (right), sign a Memorandum of Understanding today (24 August) establishing a strategic partnership to advance research and development…...

BioPharma APAC
biopharmaapac.com > company-results > 31 > 8352 > wuxi-xdc-h1-2026-revenue-jumps-37-to-rmb-3-7-bn-on-strong-bioconjugate-demand.html

WuXi XDC H1 2026 Revenue Jumps 37% to RMB 3.7 Bn on Strong Bioconjugate Demand

2+ week, 4+ day ago   (180+ words) 26 August 2026 | Wednesday | Company results WuXi XDC Cayman Inc. (the "WuXi XDC" or the "Group", stock code: 2268.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) focused on the bioconjugate market, is pleased to announce its interim results for…...

BioPharma APAC
biopharmaapac.com > news > 122 > 8350 > biocon-partners-with-innomar-strategies-to-strengthen-canada-supply-chain.html

Biocon Partners with Innomar Strategies to Strengthen Canada Supply Chain

2+ week, 6+ day ago   (142+ words) 24 August 2026 | Monday | News Biocon has partnered with Innomar Strategies, a healthcare services and logistics company, to strengthen its pharmaceutical supply chain and distribution network across Canada. Under the collaboration, Innomar Strategies will serve as Biocon’s exclusive third-party logistics (3PL) provider in…...

BioPharma APAC
biopharmaapac.com > news > 17 > 8348 > south-koreas-rznomics-joins-lilly-gateway-labs-in-us-to-accelerate-rna-gene-therapies.html

South Korea’s Rznomics Joins Lilly Gateway Labs in US to Accelerate RNA Gene Therapies

2+ week, 6+ day ago   (159+ words) 24 August 2026 | Monday | News Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that it is joining Lilly Gateway Labs (LGL) in San Diego, California. Through its entry into Lilly Gateway Labs, Rznomics plans to…...